Synapse - S. Karger AG

S. Karger AG

SHERPA: Unknown

People

Groups

Department of Medicine (2)
Melanoma and Immunotherapeutics Service (2)
Solid Tumor Oncology Division (2)
GSK Faculty (1)
Thoracic Oncology (1)

Search Within

Results (2)

Evaluation of nivolumab (nivo) alone and in combination with ipilimumab (ipi) in patients (pts) with advanced (adv) small-cell lung cancer (SCLC): First report of a randomized expansion cohort from the CheckMate 032 trial

Meeting Abstract

Atmaca, A.; Hellmann, M. D.; Ott, P. A.; Zugazagoitia, J.; Ready, N.; Hann, C. L.; De Braud, F.; Antonia, S.; Ascierto, P.; Moreno, V.; more...
Oncology Research and Treatment (2017)

Fulltext@MSK | Save

Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)

Meeting Abstract

Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M. S.; more...
Oncology Research and Treatment (2016)

Fulltext@MSK | Save

S. Karger AG

People

Groups

Results (2)

Meeting Abstract

Meeting Abstract

S. Karger AG – authorized name for: